Do analysts recommend ELUT or INGN?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Elutia 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Inogen 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.50

Which has better valuation & earnings, ELUT or INGN?

Elutia has higher earnings, but lower revenue than Inogen. Inogen is trading at a lower price-to-earnings ratio than Elutia, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Elutia $12.29M 3.06 $53.38M $0.95 0.89 Inogen $348.67M 0.39 -$22.75M -$0.90 N/A

Is ELUT or INGN more profitable?

Elutia has a net margin of 426.93% compared to Inogen's net margin of -6.94%. Inogen's return on equity of -13.17% beat Elutia's return on equity. Company Net Margins Return on Equity Return on Assets Elutia 426.93% -407.37% -47.08% Inogen -6.94% -13.17% -8.36%

Do analysts recommend OWLT or ELUT?

Owlet currently has a consensus target price of $15.00, indicating a potential upside of 218.34%. Given Owlet's stronger consensus rating and higher probable upside, analysts clearly believe Owlet is more favorable than Elutia. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Owlet 1 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.40 Elutia 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better earnings & valuation, OWLT or ELUT?

Elutia has lower revenue, but higher earnings than Owlet. Owlet is trading at a lower price-to-earnings ratio than Elutia, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Owlet $114.41M 1.20 -$39.68M -$0.75 N/A Elutia $12.29M 3.06 $53.38M $0.95 0.89

Is OWLT or ELUT more profitable?

Elutia has a net margin of 426.93% compared to Owlet's net margin of -8.61%. Elutia's return on equity of -407.37% beat Owlet's return on equity. Company Net Margins Return on Equity Return on Assets Owlet -8.61% -601.24% -15.96% Elutia 426.93% -407.37% -47.08%

Do analysts rate APYX or ELUT?

Apyx Medical currently has a consensus target price of $6.60, suggesting a potential upside of 115.69%. Given Apyx Medical's stronger consensus rating and higher probable upside, analysts clearly believe Apyx Medical is more favorable than Elutia. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Apyx Medical 1 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 2.71 Elutia 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has higher valuation & earnings, APYX or ELUT?

Elutia has lower revenue, but higher earnings than Apyx Medical. Apyx Medical is trading at a lower price-to-earnings ratio than Elutia, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Apyx Medical $58.42M 2.21 -$11.21M -$0.20 N/A Elutia $12.29M 3.06 $53.38M $0.95 0.89

Is APYX or ELUT more profitable?

Elutia has a net margin of 426.93% compared to Apyx Medical's net margin of -14.78%. Apyx Medical's return on equity of -76.60% beat Elutia's return on equity. Company Net Margins Return on Equity Return on Assets Apyx Medical -14.78% -76.60% -13.91% Elutia 426.93% -407.37% -47.08%

Do analysts rate ELUT or CNXU?

Conexeu Sciences has a consensus target price of $20.00, indicating a potential upside of 303.23%. Given Conexeu Sciences' stronger consensus rating and higher possible upside, analysts plainly believe Conexeu Sciences is more favorable than Elutia. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Elutia 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Conexeu Sciences 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Is ELUT or CNXU more profitable?

Elutia has a net margin of 426.93% compared to Conexeu Sciences' net margin of 0.00%. Conexeu Sciences' return on equity of -200.20% beat Elutia's return on equity. Company Net Margins Return on Equity Return on Assets Elutia 426.93% -407.37% -47.08% Conexeu Sciences N/A -200.20% -177.26%

Do analysts rate KEQU or ELUT?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Kewaunee Scientific 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Elutia 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Elutia (ELUT) Competitors

$0.85 0.00 (0.00%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$0.85 0.00 (-0.47%)

As of 09/18/2026 04:10 PM Eastern

Compare

ELUT vs. INGN, OWLT, APYX, CNXU, and KEQU

Should you buy Elutia stock or one of its competitors? Elutia's main competitors and comparable companies include Inogen (INGN), Owlet (OWLT), Apyx Medical (APYX), Conexeu Sciences (CNXU), and Kewaunee Scientific (KEQU). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare equipment" industry.

How does Elutia compare to Inogen?

Elutia (NASDAQ:ELUT) and Inogen (NASDAQ:INGN) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, valuation, earnings, profitability, institutional ownership, media sentiment, risk and dividends.

Elutia has a net margin of 426.93% compared to Inogen's net margin of -6.94%. Inogen's return on equity of -13.17% beat Elutia's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Elutia	426.93%	-407.37%	-47.08%
Inogen	-6.94%	-13.17%	-8.36%

In the previous week, Inogen had 1 more articles in the media than Elutia. MarketBeat recorded 1 mentions for Inogen and 0 mentions for Elutia. Elutia's average media sentiment score of 0.00 equaled Inogen'saverage media sentiment score.

Company	Overall Sentiment
Elutia	Neutral
Inogen	Neutral

Elutia has a beta of 0.88, indicating that its stock price is 12% less volatile than the broader market. Comparatively, Inogen has a beta of 1.57, indicating that its stock price is 57% more volatile than the broader market.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Elutia	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Inogen	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.50

Elutia has higher earnings, but lower revenue than Inogen. Inogen is trading at a lower price-to-earnings ratio than Elutia, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Elutia	$12.29M	3.06	$53.38M	$0.95	0.89
Inogen	$348.67M	0.39	-$22.75M	-$0.90	N/A

74.0% of Elutia shares are owned by institutional investors. Comparatively, 89.9% of Inogen shares are owned by institutional investors. 17.8% of Elutia shares are owned by company insiders. Comparatively, 2.5% of Inogen shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

Inogen beats Elutia on 8 of the 14 factors compared between the two stocks.

How does Elutia compare to Owlet?

Owlet (NYSE:OWLT) and Elutia (NASDAQ:ELUT) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, valuation, media sentiment, risk, dividends, analyst recommendations, earnings and profitability.

72.6% of Owlet shares are owned by institutional investors. Comparatively, 74.0% of Elutia shares are owned by institutional investors. 36.2% of Owlet shares are owned by insiders. Comparatively, 17.8% of Elutia shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Owlet currently has a consensus target price of $15.00, indicating a potential upside of 218.34%. Given Owlet's stronger consensus rating and higher probable upside, analysts clearly believe Owlet is more favorable than Elutia.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Owlet	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Elutia	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Owlet had 3 more articles in the media than Elutia. MarketBeat recorded 3 mentions for Owlet and 0 mentions for Elutia. Owlet's average media sentiment score of 0.51 beat Elutia's score of 0.00 indicating that Owlet is being referred to more favorably in the media.

Company	Overall Sentiment
Owlet	Positive
Elutia	Neutral

Elutia has a net margin of 426.93% compared to Owlet's net margin of -8.61%. Elutia's return on equity of -407.37% beat Owlet's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Owlet	-8.61%	-601.24%	-15.96%
Elutia	426.93%	-407.37%	-47.08%

Elutia has lower revenue, but higher earnings than Owlet. Owlet is trading at a lower price-to-earnings ratio than Elutia, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Owlet	$114.41M	1.20	-$39.68M	-$0.75	N/A
Elutia	$12.29M	3.06	$53.38M	$0.95	0.89

Owlet has a beta of 1.9, meaning that its stock price is 90% more volatile than the broader market. Comparatively, Elutia has a beta of 0.88, meaning that its stock price is 12% less volatile than the broader market.

Summary

Owlet beats Elutia on 9 of the 16 factors compared between the two stocks.

How does Elutia compare to Apyx Medical?

Apyx Medical (NASDAQ:APYX) and Elutia (NASDAQ:ELUT) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, media sentiment, profitability, valuation, analyst recommendations, institutional ownership, earnings and risk.

Apyx Medical currently has a consensus target price of $6.60, suggesting a potential upside of 115.69%. Given Apyx Medical's stronger consensus rating and higher probable upside, analysts clearly believe Apyx Medical is more favorable than Elutia.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Apyx Medical	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71
Elutia	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Apyx Medical had 2 more articles in the media than Elutia. MarketBeat recorded 2 mentions for Apyx Medical and 0 mentions for Elutia. Apyx Medical's average media sentiment score of 0.38 beat Elutia's score of 0.00 indicating that Apyx Medical is being referred to more favorably in the media.

Company	Overall Sentiment
Apyx Medical	Neutral
Elutia	Neutral

Elutia has a net margin of 426.93% compared to Apyx Medical's net margin of -14.78%. Apyx Medical's return on equity of -76.60% beat Elutia's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Apyx Medical	-14.78%	-76.60%	-13.91%
Elutia	426.93%	-407.37%	-47.08%

Elutia has lower revenue, but higher earnings than Apyx Medical. Apyx Medical is trading at a lower price-to-earnings ratio than Elutia, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Apyx Medical	$58.42M	2.21	-$11.21M	-$0.20	N/A
Elutia	$12.29M	3.06	$53.38M	$0.95	0.89

55.3% of Apyx Medical shares are held by institutional investors. Comparatively, 74.0% of Elutia shares are held by institutional investors. 15.9% of Apyx Medical shares are held by insiders. Comparatively, 17.8% of Elutia shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Apyx Medical has a beta of 1.31, indicating that its share price is 31% more volatile than the broader market. Comparatively, Elutia has a beta of 0.88, indicating that its share price is 12% less volatile than the broader market.

Summary

Apyx Medical beats Elutia on 10 of the 17 factors compared between the two stocks.

How does Elutia compare to Conexeu Sciences?

Elutia (NASDAQ:ELUT) and Conexeu Sciences (NASDAQ:CNXU) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, valuation, dividends, profitability, institutional ownership, media sentiment, earnings and analyst recommendations.

Conexeu Sciences has a consensus target price of $20.00, indicating a potential upside of 303.23%. Given Conexeu Sciences' stronger consensus rating and higher possible upside, analysts plainly believe Conexeu Sciences is more favorable than Elutia.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Elutia	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Conexeu Sciences	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

74.0% of Elutia shares are owned by institutional investors. 17.8% of Elutia shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Elutia has higher revenue and earnings than Conexeu Sciences. Conexeu Sciences is trading at a lower price-to-earnings ratio than Elutia, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Elutia	$12.29M	3.06	$53.38M	$0.95	0.89
Conexeu Sciences	N/A	N/A	-$3.92M	-$0.11	N/A

In the previous week, Conexeu Sciences had 3 more articles in the media than Elutia. MarketBeat recorded 3 mentions for Conexeu Sciences and 0 mentions for Elutia. Elutia's average media sentiment score of 0.00 beat Conexeu Sciences' score of -0.24 indicating that Elutia is being referred to more favorably in the media.

Company	Overall Sentiment
Elutia	Neutral
Conexeu Sciences	Neutral

Elutia has a net margin of 426.93% compared to Conexeu Sciences' net margin of 0.00%. Conexeu Sciences' return on equity of -200.20% beat Elutia's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Elutia	426.93%	-407.37%	-47.08%
Conexeu Sciences	N/A	-200.20%	-177.26%

Summary

Elutia beats Conexeu Sciences on 9 of the 14 factors compared between the two stocks.

How does Elutia compare to Kewaunee Scientific?

Kewaunee Scientific (NASDAQ:KEQU) and Elutia (NASDAQ:ELUT) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, analyst recommendations, media sentiment, profitability, valuation, earnings, risk and institutional ownership.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kewaunee Scientific	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
Elutia	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Kewaunee Scientific has a beta of 0.73, meaning that its share price is 27% less volatile than the broader market. Comparatively, Elutia has a beta of 0.88, meaning that its share price is 12% less volatile than the broader market.

Elutia has lower revenue, but higher earnings than Kewaunee Scientific. Elutia is trading at a lower price-to-earnings ratio than Kewaunee Scientific, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kewaunee Scientific	$282M	0.35	$9.62M	$2.76	12.36
Elutia	$12.29M	3.06	$53.38M	$0.95	0.89

In the previous week, Kewaunee Scientific had 3 more articles in the media than Elutia. MarketBeat recorded 3 mentions for Kewaunee Scientific and 0 mentions for Elutia. Kewaunee Scientific's average media sentiment score of 0.37 beat Elutia's score of 0.00 indicating that Kewaunee Scientific is being referred to more favorably in the media.

Company	Overall Sentiment
Kewaunee Scientific	Neutral
Elutia	Neutral

Elutia has a net margin of 426.93% compared to Kewaunee Scientific's net margin of 2.97%. Kewaunee Scientific's return on equity of 11.61% beat Elutia's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kewaunee Scientific	2.97%	11.61%	4.82%
Elutia	426.93%	-407.37%	-47.08%

32.7% of Kewaunee Scientific shares are held by institutional investors. Comparatively, 74.0% of Elutia shares are held by institutional investors. 14.1% of Kewaunee Scientific shares are held by insiders. Comparatively, 17.8% of Elutia shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Kewaunee Scientific beats Elutia on 8 of the 14 factors compared between the two stocks.

Get Elutia News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ELUT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ELUT vs. The Competition

Export

Metric	Elutia	Healthcare Equipment & Supplies Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$37.65M	$5.49B	$7.22B	$12.94B
Dividend Yield	N/A	1.80%	2.57%	12.80%
P/E Ratio	0.89	25.33	275.48	25.40
Price / Sales	3.06	72.75	648.15	82.07
Price / Cash	N/A	33.11	28.13	34.74
Price / Book	1.31	5.90	10.60	6.32
Net Income	$53.38M	$151.55M	$3.49B	$358.20M
7 Day Performance	8.28%	0.17%	-0.24%	0.42%
1 Month Performance	-10.61%	-3.88%	-2.67%	-3.30%
1 Year Performance	-22.02%	6.80%	18.16%	5.33%

Elutia Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ELUT Elutia	1.1812 of 5 stars	$0.85 flat	N/A	-22.0%	$37.65M	$12.29M	0.89	180	Gap Up
INGN Inogen	0.6235 of 5 stars	$5.13 -1.3%	N/A	-40.6%	$136.14M	$354.30M	N/A	753	Positive News
OWLT Owlet	2.4295 of 5 stars	$4.55 -1.9%	$15.00 +229.6%	-42.0%	$132.98M	$105.70M	N/A	114	News Coverage
APYX Apyx Medical	3.0667 of 5 stars	$3.01 +1.7%	$6.60 +119.3%	+33.6%	$126.78M	$52.84M	N/A	205
CNXU Conexeu Sciences	2.1749 of 5 stars	$4.62 +3.8%	$20.00 +332.9%	N/A	$123.62M	N/A	N/A	4	Earnings Report Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ELUT) was last updated on 9/21/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Elutia (ELUT) Competitors